logo

South America Kidney Cancer Therapeutics & Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The market is segmented by Cancer Type (Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, and Other Cancer Types), Therapeutic Class, Pharmacologic Class, Diagnostics and Geography

Home Market Analysis Healthcare Research Device Drug Combination Research Diagnostics and Therapeutics Research Oncology Research South America Kidney Cancer Therapeutics & Diagnostics Market

South America Kidney Cancer Therapeutics & Diagnostics Market Size

View Global Report
CAGR
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Historical Data Period 2019 - 2022
CAGR 6.50 %

Major Players

South America Kidney Cancer Therapeutics & Diagnostics Market

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of South America Kidney Cancer Therapeutics & Diagnostics Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

South America Kidney Cancer Therapeutics & Diagnostics Market Analysis

Kidney cancer is a disease that starts in the kidneys. It happens when healthy cells in one or both kidneys grow out of control and form a tumor. Renal cell carcinoma is the most common type of kidney cancer found in adults.

In South America, the cases of kidney cancer are on the rise. This has resulted in increasing demand for kidney therapeutics and diagnostics. Currently, there are various treatment options available and many drugs are in pipeline too, which is expected to drive the kidney cancer therapeutics and diagnostics market during the forecast period.

In addition, rising investments in research by various government bodies and the development of novel drugs by pharmaceutical and biotechnology companies are other major contributing factors. Hence all these factors are expected to help the growth of kidney cancer and therapeutics market in South America.

South America Kidney Cancer Therapeutics & Diagnostics Market Trends

This section covers the major market trends shaping the South America Kidney Cancer Therapeutics & Diagnostics Market according to our research experts:

Application in Renal Cell Carcinoma is expected to Dominate the Market

Renal cell carcinoma is the most common type of adult kidney cancer, making up about 85% of diagnoses. This type of cancer develops in the proximal renal tubules that make up the kidney’s filtration system. There are thousands of these tiny filtration units in each kidney.

In South America, the prevalence of kidney cancer is expected to rise as per the estimates by the International Agency for Research on Cancer 2018 data. As renal cell carcinoma is most common type of cancer, the demand for its therapeutics and diagnostics is expected to rise as well. In addition, there are also other factors that are driving the market that includes growing awareness among people about cancer, the increased diagnostic rates, rising geriatric population, and rising incidence of renal cancer.

Graph.png

South America Kidney Cancer Therapeutics & Diagnostics Industry Overview

South America is a developing region. Although the healthcare system in many countries in the region are not highly developed, these countries are spending more each year in their healthcare system. This has encouraged many global companies to enter the market and as a result, many global players in the patient monitoring market are present in the region. These factors have made the region very competitive.

South America Kidney Cancer Therapeutics & Diagnostics Market Leaders

  1. Eisai

  2. Bristol Myers Squibb Company

  3. Exelixis

  4. Novartis International AG

  5. Bayer AG

*Disclaimer: Major Players sorted in no particular order

Concentration.png
Need More Details on Market Players and Competitors?
Download PDF

South America Kidney Cancer Therapeutics & Diagnostics Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Number of Kidney Cancer Case

      2. 4.2.2 Increased R&D Expenditure of Pharmaceutical Companies

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost Associated with Treatment

      2. 4.3.2 Low Success Rate in Clinical Trials for Cancer Drugs

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Cancer Type

      1. 5.1.1 Renal Cell Carcinoma

      2. 5.1.2 Clear Cell Renal Cell Carcinoma

      3. 5.1.3 Papillary Renal Cell Carcinoma

      4. 5.1.4 Other Cancer Types

    2. 5.2 By Therapeutic Class

      1. 5.2.1 Targeted Therapy

      2. 5.2.2 Immunotherapy

    3. 5.3 By Pharmacologic Class

      1. 5.3.1 Angiogenesis Inhibitors

      2. 5.3.2 Monoclonal Antibodies

      3. 5.3.3 mTOR Inhibitors

      4. 5.3.4 Others

    4. 5.4 By Diagnostics

      1. 5.4.1 Biopsy

      2. 5.4.2 Intravenous Pyelogram

      3. 5.4.3 CT Scan

      4. 5.4.4 Ultrasound

      5. 5.4.5 Other Diagnostics

    5. 5.5 Geography

      1. 5.5.1 South America

        1. 5.5.1.1 Brazil

        2. 5.5.1.2 Argentina

        3. 5.5.1.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories

      2. 6.1.2 Amgen Inc.

      3. 6.1.3 Bayer AG

      4. 6.1.4 Bristol-Myers Squibb Company

      5. 6.1.5 Eisai

      6. 6.1.6 Exelixis

      7. 6.1.7 F. Hoffmann-La Roche

      8. 6.1.8 GlaxoSmithKline PLC

      9. 6.1.9 Novartis International AG

      10. 6.1.10 Pfizer Inc.

    2. *List Not Exhaustive

  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

South America Kidney Cancer Therapeutics & Diagnostics Industry Segmentation

As per the scope of the report, kidney cancer is a type of cancer which starts in kidney cells. The kidney cancer therapeutics and diagnostics involves therapy and diagnostics methods that are used for the treatment of renal cancer. The drugs are used for the treatment of various type of kidney cancers.

By Cancer Type
Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
Papillary Renal Cell Carcinoma
Other Cancer Types
By Therapeutic Class
Targeted Therapy
Immunotherapy
By Pharmacologic Class
Angiogenesis Inhibitors
Monoclonal Antibodies
mTOR Inhibitors
Others
By Diagnostics
Biopsy
Intravenous Pyelogram
CT Scan
Ultrasound
Other Diagnostics
Geography
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

South America Kidney Cancer Therapeutics & Diagnostics Market Research FAQs

The South America Kidney Cancer Therapeutics & Diagnostics Market is projected to register a CAGR of 6.5% during the forecast period (2024-2029)

Eisai, Bristol Myers Squibb Company, Exelixis , Novartis International AG and Bayer AG are the major companies operating in the South America Kidney Cancer Therapeutics & Diagnostics Market.

The report covers the South America Kidney Cancer Therapeutics & Diagnostics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the South America Kidney Cancer Therapeutics & Diagnostics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

South America Kidney Cancer Therapeutics & Diagnostics Industry Report

Statistics for the 2024 South America Kidney Cancer Therapeutics & Diagnostics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. South America Kidney Cancer Therapeutics & Diagnostics analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

South America Kidney Cancer Therapeutics & Diagnostics Report Snapshots

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

South America Kidney Cancer Therapeutics & Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)